HTG EdgeSeq™ Reveal Immunophenotyping Signatures
HTG EdgeSeq™ Reveal Immunophenotyping Signatures
- Categories
- White Papers
- Topics:
- Reveal
- Signatures
HTG EdgeSeq™ Reveal Immunophenotyping Signatures
Bustos, M. A., et al. Integrated Assessment of Circulating Cell-Free MicroRNA signatures in Plasma of Patients With Melanoma Brain Metastasis. Cancers 2020, 12, 1692; doi:10.3390/cancers12061692
Danza, J., et al. HLA-E Expression Predicts Progression, Therapeutic Response and Overall Survival in Patients with Bladder Cancer. The Journal of Urology 2020 APR: 203(4) e228-e229.
Koshkin, V. S., et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research. 2019 Jan 1; 25(1) 210-221.
Knudsen E., et al. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunological Markers. Clin Cancer Res. 2017 Aug 1;23(15):4429
PMID: 28348045
Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312
PMID: 28131785
Page last updated May 22, 2023